Company / SG&A Expense
Sonoma Pharmaceuticals, Inc. SG&A Expense History
FY2017-FY2026 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$7.4M
FY2026
5-year range
$7.4M / $9.8M
FY2022-FY2026
Trend
-2.8%
vs FY2025
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has declined for 3 consecutive years, from $10M in FY2023 to $7M in FY2026.
Based on SEC 10-K filings.
$7M in FY2026 with a 5-year CAGR of -12.3%.
Improved from $9M to $7M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -9.0%
- 5-Year CAGR
- -12.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- Sonoma Pharmaceuticals, Inc.'s sg&a expense has declined for 3 consecutive years.
- 5-year CAGR of -12.3%, indicating a declining trend.
- In FY2026, sg&a expense decreased 2.8% year-over-year.
- Peak sg&a expense was recorded in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2026 | $7.4M | -2.8% |
| FY2025 | $7.6M | -14.3% |
| FY2024 | $8.8M | -9.4% |
| FY2023 | $9.8M | +3.2% |
| FY2022 | $9.5M | -33.3% |
| FY2021 | $14.2M | -23.9% |
| FY2020 | $18.6M | -6.5% |
| FY2019 | $19.9M | +16.7% |
| FY2018 | $17.1M | +9.7% |
| FY2017 | $15.6M | +25.3% |
As of FY2026 · SEC 10-K · Updated Jun 28, 2026